Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: BUY (auto-tracking)
0.70% $11.54
America/New_York / 26 apr 2024 @ 15:09
FUNDAMENTALS | |
---|---|
MarketCap: | 709.68 mill |
EPS: | -1.080 |
P/E: | -10.69 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 61.50 mill |
Avg Daily Volume: | 0.592 mill |
RATING 2024-04-26 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -10.69 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.22x |
Company: PE -10.69 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 11.03 - 12.05 ( +/- 4.38%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Moatazedi David | Sell | 6 236 | Common Stock |
2024-03-19 | Avelar Rui | Sell | 27 603 | Common Stock |
2024-03-19 | Beaver Sandra | Sell | 5 672 | Common Stock |
2024-03-19 | Moatazedi David | Sell | 96 566 | Common Stock |
2024-02-21 | Moatazedi David | Buy | 61 202 | Common Stock |
INSIDER POWER |
---|
-27.00 |
Last 98 transactions |
Buy: 3 096 818 | Sell: 6 427 203 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $11.54 (0.70% ) |
Volume | 0.124 mill |
Avg. Vol. | 0.592 mill |
% of Avg. Vol | 20.97 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $13.31 | N/A | Active |
---|
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.